Can we select NSCLC patients for immune checkpoint therapy?

37 / 38

Hyperprogressive disease
Ferrara – WCLC 2017
N = 406
14% HPD with IO vs . 5% with CT
HR 1.55 [95% CI 1.07;2.25]
OS